Amgen Gets The First BiTE
On December 3, FDA approved Amgen Inc.’s bispecific T-cell engager (BiTE) Blincyto for forms of relapsed or refractory acute lymphocytic leukemia, less than two months after accepting the company’s Biologics License Application and more than five months ahead of its user-fee goal of May 19, 2015.
You may also be interested in...
The oncology community believes that immunotherapy will be foundational, in the same way that combination chemotherapy became the backbone of treatment in the 1970s. The marching order is to trial broadly, quickly, making clinical development particularly well-suited for Big Pharma.
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.